Daewon Pharmaceutical is showing strong performance. This is interpreted as being influenced by the news that the new drug candidate for obesity treatment, for which Daewon Pharmaceutical holds domestic distribution rights, has signed a Material Transfer Agreement (MTA) with a multinational pharmaceutical company famous for obesity treatments.
As of 9:51 AM on the 22nd, Daewon Pharmaceutical is trading at 16,960 KRW, up 3.79% from the previous day.
According to the bio industry, Glaceum, which is developing the once-daily oral obesity treatment new drug candidate ‘HSG4112,’ has signed a Material Transfer Agreement (MTA) with a multinational pharmaceutical company renowned for obesity treatments.
The most notable obesity treatments worldwide currently are GLP-1 receptor agonists. Representative drugs include Wegovy from Denmark’s Novo Nordisk and Mounjaro from Eli Lilly.
Glaceum administered HSG4112 and Wegovy to obese mice and compared the results over six weeks. The average weight of the obese mice was 40g, and the experiment showed that while Wegovy reduced and stabilized the weight at 34g, HSG4112 reduced it to the normal weight of 20g.
Meanwhile, Daewon Pharmaceutical holds the domestic distribution rights for HSG4112. Daewon Pharmaceutical is preparing for Phase 2 clinical trials of HSG4112 in Korea.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
